Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical manufacturer and developer Penn Pharma has announced a £14m investment in its South Wales UK facility to strengthen its offering for international supply and further build on the company's manufacturing capabilities.
Subscribe to our email newsletter
The investment sees the company expand its containment facilities with a 15,000sq ft new development and commercial manufacturing unit for tablets and capsules.
The new facility will enable the team at Penn to further build upon its manufacturing capabilities in regard to specialist drugs for the global market.
Penn Pharma chief executive Richard Yarwood said the investment is the catalyst required to enable the company to build on the services that it currently offering its clients and ensure that the company is able to react to the evolving market place.
"We have seen a growth in the number of highly potent compounds coming through the pharmaceutical early phase pipeline and in response to this we are investing in an expansion of our existing resources to meet this growing demand," Yarwood said.
The company claims that the new facility will see the team at Penn build on their success in the oncology and orphan drug sector and allow for more frequent and larger scale project delivery.